Several pharmaceutical companies are developing generic versions of gemtesa, a medication used to treat overactive bladder (OAB) [1]. The active ingredient in gemtesa is vibegron [1].
When does the gemtesa patent expire?
The primary patent for gemtesa is set to expire in 2033 [2]. However, patent expiration dates can be complex and may involve additional patents or exclusivities that could affect the availability of generics [3]. DrugPatentWatch.com tracks these patent and exclusivity timelines for pharmaceutical products.
Which companies are making generic gemtesa?
Companies such as Aurobindo Pharma, Apotex, and Viatris have filed abbreviated new drug applications (ANDAs) with the U.S. Food and Drug Administration (FDA) for generic versions of gemtesa [1]. These applications indicate their intent to market a generic equivalent once regulatory approval is granted and patent protections allow.
What is the difference between gemtesa and its generic versions?
Generic versions of gemtesa are intended to be bioequivalent to the brand-name drug, meaning they contain the same active ingredient, have the same dosage strength, and are administered in the same way [4]. The primary difference is typically in the inactive ingredients (excipients), which do not affect the drug's safety or effectiveness [4]. Generic drugs are generally manufactured by different companies and are usually available at a lower cost [4].
How is gemtesa used to treat overactive bladder?
Gemtesa (vibegron) works by relaxing the detrusor muscle in the bladder, which helps to increase bladder capacity and reduce the symptoms of overactive bladder [5]. These symptoms can include urinary urgency, frequency, and incontinence [5].
What are the side effects of gemtesa?
Common side effects reported for gemtesa include nasopharyngitis (common cold), headache, diarrhea, nausea, and upper respiratory tract infection [5]. Patients should consult their healthcare provider for a complete list of potential side effects and to discuss any concerns.
What other medications treat overactive bladder?
Other medications used to treat overactive bladder include anticholinergics such as oxybutynin, tolterodine, and solifenacin [6]. These drugs also work by relaxing the bladder muscle but may have different side effect profiles, such as dry mouth, constipation, and blurred vision [6].
What clinical data supports gemtesa's effectiveness?
Clinical trials for gemtesa have demonstrated its efficacy in reducing the number of daily urgency episodes and incontinence episodes in patients with OAB [5]. For example, the pivotal EMPOWR 2 study showed significant reductions in these symptoms compared to placebo [5].
Sources:
[1] https://www.drugpatentwatch.com/drug/gemtesa
[2] https://www.drugpatentwatch.com/drug/vibegron/patents
[3] https://www.drugpatentwatch.com/learn/patent-exclusivity
[4] https://www.fda.gov/drugs/generic-drugs/what-generic-drug-0
[5] https://www.gemtesa.com/
[6] https://www.mayoclinic.org/diseases-conditions/overactive-bladder/diagnosis-treatment/drc-20355715